The role of Gliadel wafers in the treatment of high-grade gliomas

Expert Review of Anticancer Therapy

Volumn 13, Issue 12, 2013, Pages 1453-1461

  Bregy, Amade ^a   Shah, Ashish H ^a   Diaz, Maria V ^a   Pierce, Hayley E ^a   Ames, Philip L ^a   Diaz, Daniel ^a   Komotar, Ricardo J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Carmustine; Chemotherapy; Gliadel wafers; Glioblastoma multiforme

Indexed keywords

CARMUSTINE; PLACEBO; POLYMER; TEMOZOLOMIDE;

ABSCESS; ADJUVANT CHEMORADIOTHERAPY; ADULT; ANEMIA; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; BRAIN ABSCESS; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CYST; DEEP VEIN THROMBOSIS; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG SAFETY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; LEUKOPENIA; LIQUORRHEA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENINGOCELE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PNEUMONIA; REVIEW; SEIZURE; SURVIVAL TIME; SYSTEMIC DISEASE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

BRAIN NEOPLASMS; CARMUSTINE; DECANOIC ACIDS; GLIOBLASTOMA; GLIOMA; HUMANS; MIDDLE AGED; POLYESTERS;

EID: 84888241166     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.840090     Document Type: Review

References (36)

1. Affronti ML, Heery CR, Herndon JE 2nd et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115, 3501-3511 (2009).
2. Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther. Clin. Risk Manag. 3, 707-715 (2007).
3. Buonerba C, Di Lorenzo G, Marinelli A et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit. Rev. Oncol. Hematol. 80, 54-68 (2011).
4. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J. Neurooncol. 72, 241-244 (2005).
5. Attenello FJ, Mukherjee D, Datoo G et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann. Surg. Oncol. 15, 2887-2893 (2008).
6. Mangiola A, de Bonis P, Maira G et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113(4), 841-846 (2008).
7. Mangiola A, Saulnier N, De Bonis P et al. Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PloS ONE 8(3), e57145 (2013).
8. Prager JM, Grenier Y, Cozzens JW, Chiowanich P, Gorey MT, Meyer JR. Serial CT and MR imaging of carmustine wafers. AJNR Am. J. Neuroradiol. 21(1), 119-123 (2000).
9. Dyke JP, Sanelli PC, Voss HU et al. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J. Neurooncol. 82, 103-110 (2007).
10. Balossier A, Dörner L, Emery E et al. Incorporating BCNU wafers into malignant glioma treatment: European case studies. Clin. Drug Investig. 30, 195-204 (2010).
11. Panigrahi M, Das PK, Parikh PM. Brain tumor and Gliadel wafer treatment. Indian J. Cancer 48(1), 11-7 (2011).
12. McGovern PC, Lautenbach E, Brennanl PJ, Lustig RA, Fishman NO. 0 Risk Factors for Postcraniotomy Surgical Site Infection after 1, 3-Bis (2-Chloroethyl) - 1-Nitrosourea (Gliadel) Wafer Placement. Clin. Infect. Dis. 2699, 759-765 (2003).
13. Gallego JM, Barcia JA, Barcia-Mariño C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta neurochir. 149, 261-265, discussion 265 (2007).
14. Giese A, Kucinski T, Knopp U et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J. Neurooncol. 66(3), 351-360 (2004).
15. Stupp R, Hegi ME, Mason WP. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
16. Miglierini P, Bouchekoua M, Rousseau B, Hieu PD, Malhaire JP, Pradier O. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin. Neurol. Neurosurg. 114(9), 1222-1225 (2012).
17. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta neurochir. 148, 269-275, discussion 275 (2006).
18. Menei P, Metellus P, Parot-Schinkel E et al.; Neuro-oncology Club of the French Society of Neurosurgery. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann. Surg. Oncol. 17, 1740-1746 (2010).
19. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg. Neurol. 53(5), 458-464 (2000).
20. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1), 44-48, discussion 48-49 (1997).
21. Noël G, Schott R, Froelich S et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 749-755 (2012).
22. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg. 110, 583-588 (2009).
23. Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat. Rev. 9(4), 313-330 (1982).
24. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial Chemotherapy of the 9L Gliosarcoma: Controlled Release Polymers for Drug Delivery in the Brain. Cancer Res. 53(2), 329-333 (1993).
25. Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother. Pharmacol. 65, 137-142 (2009).
26. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 79(3-4), 141-152 (2006).
27. De Bonis P, Anile C, Pompucci A. et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir. (Wien), 154(8), 1371-1378 (2012).
28. Lechapt-Zalcman E, Levallet G, Dugué AE et al. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118(18), 4545-4554 (2012).
29. Ulmer S, Spalek K, Nabavi A et al. Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro. Oncol. 14(4), 482-490(2012).
30. Chaichana KL, Zaidi H, Pendleton C et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol. Res. 33(7), 759-764 (2011).
31. Della Puppa A, Rossetto M, Ciccarino P et al. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series. World Neurosurg. 76(1-2), 156-159; discussion 67-8 (2011).
32. Salmaggi A, Milanesi I, Silvani A et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J. Neurosurg. 118(4), 821-829 (2013).
33. Duntze J, Litré CF, Eap C et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann. Surg. Oncol. 20(6), 2065-2072 (2013).
34. Smith KA, Ashby LS, Gonzalez LF et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J. Neurosurg. 109(Suppl.)106-117 (2008).
35. Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies. Neuro. Oncol. 7(1), 84-89 (2005).
36. Kleinberg LR, Weingart J, Burger P et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest. 22(1), 1-9 (2004).